Prostate Cancer and Prostatic Diseases最新文献_第2页

A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location.

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-02-07 DOI: 10.1038/s41391-025-00946-z

Vincenzo Ficarra, Gabriele Sorce, Maurizio Martini, Andres Matoso, Cosimo De Nunzio

引用次数: 0

Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer.

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-02-06 DOI: 10.1038/s41391-025-00947-y

Nicolas Vial, Thomas Zilli

引用次数: 0

Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy.

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-31 DOI: 10.1038/s41391-025-00936-1

Georges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, Yeonjung Jo, Arshit Narang, Beverly Chigarira, Nishita Tripathi, Ayana Srivastava, Clara Tandar, Jessica F Williams, Diya Garg, Richard Ji, Benjamin L Maughan, Umang Swami, Neeraj Agarwal

{"title":"Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy.","authors":"Georges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, Yeonjung Jo, Arshit Narang, Beverly Chigarira, Nishita Tripathi, Ayana Srivastava, Clara Tandar, Jessica F Williams, Diya Garg, Richard Ji, Benjamin L Maughan, Umang Swami, Neeraj Agarwal","doi":"10.1038/s41391-025-00936-1","DOIUrl":"https://doi.org/10.1038/s41391-025-00936-1","url":null,"abstract":"Introduction: Androgen deprivation therapy intensification (ADTi) with androgen receptor pathway inhibitors (ARPI), docetaxel or both has been shown to improve survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Currently, baseline tumor genomic markers have no role in clinical decision-making in patients with mHSPC.Methods: In this IRB-approved retrospective study, patients diagnosed with mHSPC who underwent comprehensive genomic profiling from primary tissue or metastatic sites and treated with ADTi were included. Genomic alterations with an incidence ≥5% were included in the analysis.Results: A total of 276 patients were eligible and included in the study. In the multivariable analysis, TP53 (HR 1.71, 95% CI 1.17-2.49, p = 0.006), RB1 (HR 2.32, 95% CI 1.28-4.18, p = 0.006), PTEN (HR 1.74, 95% CI 1.12-2.7, p = 0.014), and BRCA2 (HR 2.64, 95% CI 1.42-4.92, p = 0.003) were associated with significantly shorter PFS, while TP53 (HR 1.63, 95% CI 1.00-2.64, p = 0.049), RB1 (HR 4.5, 95% CI 2.32-8.70, p < 0.001), and PTEN (HR 2.4, 95% CI 1.38-4.2, p = 0.003) were associated with significantly worse OS.Conclusions: This is one of the largest studies to show the association of baseline tumor genomic markers with survival in patients with mHSPC treated with ADTi. Upon external validation, these results may aid in developing a clinical-genomic risk stratification model, patient counseling, and prognostication.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted and perilesional biopsy: triumphs and cautions.

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-27 DOI: 10.1038/s41391-025-00945-0

Xingkang Jiang, Baojie Ma, Yong Xu

引用次数: 0

Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications.

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-25 DOI: 10.1038/s41391-025-00942-3

Yu-Hsiang Lin, I-Hung Shao, Kuo-Jen Lin

引用次数: 0

Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants. 低阈值前列腺特异性抗原筛查男性致病性BRCA1/2变异。

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-21 DOI: 10.1038/s41391-025-00938-z

Hein V Stroomberg, Klaus Brasso, Anna A Blak, Anna Byrjalsen, Thomas van Overeem Hansen, Andreas Røder

{"title":"Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants.","authors":"Hein V Stroomberg, Klaus Brasso, Anna A Blak, Anna Byrjalsen, Thomas van Overeem Hansen, Andreas Røder","doi":"10.1038/s41391-025-00938-z","DOIUrl":"https://doi.org/10.1038/s41391-025-00938-z","url":null,"abstract":"Background: Men with pathogenic BRCA1/2 variants are at higher risk of prostate cancer We included men with likely pathogenic/pathogenic (LP/P) variants in BRCA1/2 in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic BRCA1/2 variants.Methods: From 2014 to 2023 a total of 340 men were included in the program. We report demographics, clinical characteristics, and treatment outcomes at 7 years.Results: The cumulative incidence of a primary biopsy was 37% (95CI: 31‒43) after 7 years. Incidence of prostate cancer diagnosis was 11% (95CI: 7.1‒15). Men referred were 7.8 (95CI: 5.3‒11, p < 0.001) times more likely to be diagnosed with prostate cancer than the general Danish male population. The cumulative incidence of biochemical failure (PSA > = 0.2 ng/ml) 4 years after RP was 22% (95CI: 2.3‒41). The main limitation is that not all men underwent a pre-biopsy MRI.Conclusion: We found a high incidence of prostate cancer in men with LP/P BRCA1/2 variants, but this may be explained by the low PSA threshold for scheduling biopsies. More studies are needed to compare this patient population to men with other germline features. The high risk of recurrence after curative therapy is worrisome and requires further evaluation as to whether this is a biological phenomenon.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When precision meets prostate cancer: the rising role of HIFU focal therapy. 当精准遇上前列腺癌：HIFU局灶治疗的作用日益提升。

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-20 DOI: 10.1038/s41391-025-00940-5

Jeremy Yuen-Chun Teoh, Chris Ho-Ming Wong

引用次数: 0

Best of 2024 in Prostate Cancer and Prostatic diseases 2024年最佳前列腺癌和前列腺疾病。

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-20 DOI: 10.1038/s41391-025-00941-4

Cosimo De Nunzio

引用次数: 0

Prognostic value of MR visibility/invisibility in men on Active Surveillance. 主动监测男性MR可见性/不可见性的预后价值。

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-17 DOI: 10.1038/s41391-024-00932-x

Laurence Klotz, Andrew Loblaw, Liying Zhang, Alexandre Mamedov, Danny Vesprini

{"title":"Prognostic value of MR visibility/invisibility in men on Active Surveillance.","authors":"Laurence Klotz, Andrew Loblaw, Liying Zhang, Alexandre Mamedov, Danny Vesprini","doi":"10.1038/s41391-024-00932-x","DOIUrl":"https://doi.org/10.1038/s41391-024-00932-x","url":null,"abstract":"Objective: We sought to determine, in a prospective long term cohort, the prognostic value of negative MR imaging with respect to upgrading and need for intervention in men on AS.Method: A long term prospective single centre study of men on Active surveillance with MR imaging. Primary outcome was upgrading on biopsy and rate of intervention. After incorporation of MRI into the AS protocol in 2013, men with negative imaging underwent systematic biopsy only for cause.Results: Five hundred and thirty AS patients had one or more MRI, with median follow-up of 8.5 years. At baseline, 39 patients (7.4%) had negative MRIs 161 (30%) equivocal, and 330 (62%) had a positive MRI. Two hundred and twenty-nine patients were upgraded; 5% with invisible lesions, 34% with PiRADS 3, and 52% with PiRADS 4-5. Two hundred and twenty-nine (43%) of the 530 men were eventually treated. No patient with a negative PiRADS was treated, vs 36% with PiRADS 3 and 52% with PiRADS 4-5 (p < 0.001). In 331 men with serial MRIs, upgrading occurred in 46% of men with stable or improved MRI, and 57% in those with MRI progression. In the 70 patients whose MRI improved from PiRADS 4-5 to 3, 46% were upgraded. No patients who transitioned from PiRADS 3-5 to 1-2 were upgraded. Time to grade progression was highly inversely correlated with PIRADS score.Conclusion: MRI invisible cancers demonstrated dramatically reduced rates of progression and no patient required intervention. Despite the absence of routine biopsies in the MR negative group, none of these patients progressed over time to GG ≥ 3 or metastatic disease. This suggests that, in men on active surveillance, image guided management, restricting biopsies to targeted biopsies of regions of interest, is sufficient to identify clinically significant cancers.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Creta, M., Shariat, S.F., Marra, G. et al. Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2024). 回复：Creta， M., sharat, s.f., Marra， G.等。外束放疗后放射复发前列腺癌患者的局部挽救治疗：系统回顾和荟萃分析。前列腺癌前列腺疾病（2024）。

IF 5.1 2区医学

Prostate Cancer and Prostatic Diseases Pub Date : 2025-01-10 DOI: 10.1038/s41391-024-00935-8

A Pati-Alam, M Fittall, J Withington, S Heavey

引用次数: 0